Medicamen Biotech Limited (MBL) is a research-driven pharmaceutical company focusing on developing, manufacturing, and marketing finished dosage formulations globally.

MBL has a strong presence in over 40 countries and is a key player in the Indian oncology segment with its own sales force and branding team.

The company operates three advanced pharmaceutical manufacturing facilities in India, capable of producing a wide range of therapeutic categories.

MBL has undertaken strategic expansions, including substantial investments in manufacturing infrastructure, to meet increasing demand in both domestic and international markets.

The acquisition of OPAL Pharmaceuticals Pty Ltd enhanced MBL's capabilities and market reach, particularly in the oncology product line.